Management & Regulatory

FDA Fast Tracks J&J’s Nipocalimab for Lupus Treatment
Management & Regulatory FDA Fast Tracks J&J’s Nipocalimab for Lupus Treatment

Modern medicine often forces patients with systemic lupus erythematosus into a difficult trade-off between managing life-threatening organ damage and enduring the harsh, systemic toxicity of long-term steroid use. While existing treatments offer some relief, they frequently fail to address the

Natural Cycles Sued for Sharing Sensitive Fertility Data
Management & Regulatory Natural Cycles Sued for Sharing Sensitive Fertility Data

The digital age has transformed how individuals manage their most intimate health details, yet a recent legal filing suggests that the promise of absolute privacy might be more of a marketing strategy than a technical reality. Natural Cycles, the first company to receive FDA clearance for a digital

NICE Approves First Vitiligo Repigmentation Cream for NHS
Management & Regulatory NICE Approves First Vitiligo Repigmentation Cream for NHS

For decades, millions of individuals living with vitiligo have navigated a healthcare system that largely dismissed their condition as a minor cosmetic inconvenience rather than a significant autoimmune challenge. This landscape shifted decisively following the approval of ruxolitinib (Opzelura) by

Is No-Log Diabetes Management Finally Here?
Management & Regulatory Is No-Log Diabetes Management Finally Here?

The relentless cycle of monitoring, calculating, and dosing that defines daily life for millions with type 1 diabetes has long been a significant source of mental and emotional strain. Managing the condition often feels like a full-time job, where every meal and snack requires meticulous

Can Deupirfenidone Transform Pulmonary Fibrosis Care?
Management & Regulatory Can Deupirfenidone Transform Pulmonary Fibrosis Care?

The medical community continues to face a significant challenge in treating idiopathic pulmonary fibrosis, a terminal respiratory condition that affects hundreds of thousands of individuals worldwide by scarring lung tissue and making breathing increasingly difficult over time. Current

Is Kygevvi the New Hope for a Fatal Rare Disease?
Management & Regulatory Is Kygevvi the New Hope for a Fatal Rare Disease?

For families and physicians navigating the devastating course of thymidine kinase 2 deficiency (TK2d), the journey has long been one of managing inevitable decline with no approved therapeutic options available in Europe. This extremely rare and severe genetic mitochondrial disease relentlessly

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later